X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -531.8 34.8 - View Chart
P/BV x 0.2 5.6 2.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
DIVIS LABORATORIES
Mar-17
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1431,222 11.7%   
Low Rs65784 8.3%   
Sales per share (Unadj.) Rs324.2153.1 211.7%  
Earnings per share (Unadj.) Rs6.439.9 16.0%  
Cash flow per share (Unadj.) Rs40.644.6 91.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs366.0201.8 181.3%  
Shares outstanding (eoy) m12.34265.47 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.6 4.9%   
Avg P/E ratio x16.225.1 64.6%  
P/CF ratio (eoy) x2.622.5 11.4%  
Price / Book Value ratio x0.35.0 5.7%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m1,282266,266 0.5%   
No. of employees `0000.99.7 9.3%   
Total wages/salary Rs m2514,687 5.4%   
Avg. sales/employee Rs Th4,430.14,175.0 106.1%   
Avg. wages/employee Rs Th278.0481.5 57.7%   
Avg. net profit/employee Rs Th87.61,089.3 8.0%   
INCOME DATA
Net Sales Rs m4,00040,643 9.8%  
Other income Rs m23749 3.0%   
Total revenues Rs m4,02341,392 9.7%   
Gross profit Rs m78514,460 5.4%  
Depreciation Rs m4221,233 34.2%   
Interest Rs m34423 1,520.8%   
Profit before tax Rs m4213,953 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-373,349 -1.1%   
Profit after tax Rs m7910,604 0.7%  
Gross profit margin %19.635.6 55.1%  
Effective tax rate %-87.924.0 -366.2%   
Net profit margin %2.026.1 7.6%  
BALANCE SHEET DATA
Current assets Rs m2,60640,105 6.5%   
Current liabilities Rs m1,9806,595 30.0%   
Net working cap to sales %15.682.5 19.0%  
Current ratio x1.36.1 21.6%  
Inventory Days Days128119 108.2%  
Debtors Days Days4381 53.5%  
Net fixed assets Rs m5,35319,995 26.8%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m4,39353,043 8.3%   
Net worth Rs m4,51653,574 8.4%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29161,585 13.5%  
Interest coverage x1.1618.4 0.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.7 73.1%   
Return on assets %5.117.3 29.6%  
Return on equity %1.819.8 8.8%  
Return on capital %6.326.1 24.1%  
Exports to sales %00-   
Imports to sales %18.425.2 72.9%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m73610,259 7.2%   
Fx inflow Rs m035,384 0.0%   
Fx outflow Rs m73610,399 7.1%   
Net fx Rs m-73624,985 -2.9%   
CASH FLOW
From Operations Rs m99711,493 8.7%  
From Investments Rs m-461-11,372 4.1%  
From Financial Activity Rs m-571-93 613.3%  
Net Cashflow Rs m-3528 -123.6%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Energy and IT Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 25, 2018 02:05 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS